吸入性支氣管擴張劑"Salbutamol"對漸進與耐力運動表現及心肺功能影響

Translated title of the contribution: The Effect of Inhaled Bronchodilator "Salbutamol" on the Progressive and Endurance Exercise Performance and Cardiorespiratory Function

Research output: Book/ReportOther report

Abstract

 Sallbutamol is a selected β-adrenoreceptor agnoist which can relax the bronchial smooth muscle. The effect of salbutamol on the cardiorespiratory responses during a progressive maximal exercise test and a 30-min endurance exercise test were studied in nine male nonasthmatic trained runners (maximum oxygen uptake, VO2max: 60.9 ml.kg1.min-1). Sabutamol (2.5 mg/2.5 ml) or placebo (2.5 ml 0.9% NaCI) was administered by an air driven nebuliser, 30 minutes prior to testing in a double-blind, counterbalanced design. Vital capacity (VC), forced vital capacity (FVC), forced expiatory volume in one second (FEV1), forced mid-expiatory flow (FEF25%-75%), and maximun voluntary ventilation (MVV) were assessed before the progressive exercise, during which maximum heart rate (HR max), VO2 max, and maximum minute ventilation (VE max) were measured. After a minium of 48 hours, the subject was administered with the same medicine to test for the 30-min inclined treadmill running endurance test, during which heart rate (HR), minute ventilation (VE), oxygen uptake (VO2), carbon dioxide output (VCO2), and respiratory exchange ratio (RER) were measured. After each exercise, pulmonary funions were measured to compare with the values before exercise. The FEF25-75% (5.36±1.06 vs 4.78±1.17 L.s-1), MVV (192.9±28.3vs180.0±27.9 L.min1), and resting heart rate (HRrest: 63.1±8.4vs59.2±7.6 bpm) in salbutamol were significantly (p<.05) higher than that of placebo. The placebo' FEF25-75% (5.35±1.07 vs 4.78± 1.17L.s-1) increased significantly (p<.05) after the endurance exercise. No significant improvement was found on total work and average work rate in the endurance exercise after salbutamol treatment. The cardiorespiratory responses during the two exercise tests were found similar between the two conditions. It was concluded the effect of salbutamol on HRrest was more significant at rest than during exercise. Although endurance performance was not improved, salbutamol introduecd a large respiratory reserve, probably related to a decrease of airway resistance.
Original languageTraditional Chinese
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Albuterol
Bronchodilator Agents
Ventilation
Heart Rate
Exercise Test
Vital Capacity
Placebos
Oxygen
Airway Resistance
Nebulizers and Vaporizers
Carbon Dioxide
Smooth Muscle
Air
Medicine
Lung

Keywords

  • bronchodilatoor
  • pulmonary function
  • progressive exercise
  • endurance exercise
  • maximum oxygen uptake

Cite this

@book{adae0fd5eb724f7b8e5b7cb07faf2ac6,
title = "吸入性支氣管擴張劑{"}Salbutamol{"}對漸進與耐力運動表現及心肺功能影響",
abstract = "貝他二型支氣管擴張劑salbutamol是一種選擇性的腎上線素感受體作用劑,能促進支氣管平滑肌的擴張。本實驗以9位男性、無氣喘病的長跑選手(vo2max:60.9±2.34ml.kg-1.min-1)為受試對象,實驗設計採雙盲、平衡(counterbalanced) 重覆測試。每位受試者於實驗前30分鐘吸入霧態2.5mg salbutamol/2.5ml或同等容量的placebo(生理食鹽水)、然後做靜止狀態下肺功能測量,項目包含:肺活量、用力肺活量、1秒用力呼氣量、25-75{\%}用力呼氣流量和最大意願通氣量,再以跑步機做漸進負荷測試(測量值包含:最大攝氣量、最大通氣量、最大心跳率),至少間隔48小時後以同一種藥物做30分鐘耐力運動(測驗值包含:運動中的心跳率、通氣量、攝氣量、二氧化碳排出量、呼吸交換率及最大輸出功與平均功率)。在每次運動測試完後立刻做肺功能測量,比較運動前後的差異。結果顯示吸入salbutamol後的25-75{\%}用力呼氣流量(5.36± 1.06比 4.78 ±1.17 L.s-1)和最大自願通氣量(192.9±28.3比180.0±27.9 L.min-1)及安靜心跳率(63.1±8.4比59.2±7.6 bpm)有顯著增加(p<.05)。漸進與30分鐘耐力運動的表現與各生理值,兩藥劑間無著差異。但於30分鐘耐力運動完後,placebo的25-75{\%}用力呼氣流量均大於運動前(5.34±1.07比4.78±1.17 L.s-1)。綜合上述結果,salbutamol對安靜狀態下心跳率影響比運動中顯著;對運動表現無顯著差異。但salbutamol 比placebo有較大的呼吸儲備,推論與呼吸阻力減少有關。",
keywords = "支氣管擴張劑, 肺功能, 漸進運動, 耐力運動, 最大攝氧量, salbutamol, bronchodilatoor, pulmonary function, progressive exercise, endurance exercise, maximum oxygen uptake",
author = "甘乃文",
note = "國立體育學院運動科學研究所碩士論文",
year = "1997",
language = "繁體中文",

}

TY - BOOK

T1 - 吸入性支氣管擴張劑"Salbutamol"對漸進與耐力運動表現及心肺功能影響

AU - 甘乃文, null

N1 - 國立體育學院運動科學研究所碩士論文

PY - 1997

Y1 - 1997

N2 - 貝他二型支氣管擴張劑salbutamol是一種選擇性的腎上線素感受體作用劑,能促進支氣管平滑肌的擴張。本實驗以9位男性、無氣喘病的長跑選手(vo2max:60.9±2.34ml.kg-1.min-1)為受試對象,實驗設計採雙盲、平衡(counterbalanced) 重覆測試。每位受試者於實驗前30分鐘吸入霧態2.5mg salbutamol/2.5ml或同等容量的placebo(生理食鹽水)、然後做靜止狀態下肺功能測量,項目包含:肺活量、用力肺活量、1秒用力呼氣量、25-75%用力呼氣流量和最大意願通氣量,再以跑步機做漸進負荷測試(測量值包含:最大攝氣量、最大通氣量、最大心跳率),至少間隔48小時後以同一種藥物做30分鐘耐力運動(測驗值包含:運動中的心跳率、通氣量、攝氣量、二氧化碳排出量、呼吸交換率及最大輸出功與平均功率)。在每次運動測試完後立刻做肺功能測量,比較運動前後的差異。結果顯示吸入salbutamol後的25-75%用力呼氣流量(5.36± 1.06比 4.78 ±1.17 L.s-1)和最大自願通氣量(192.9±28.3比180.0±27.9 L.min-1)及安靜心跳率(63.1±8.4比59.2±7.6 bpm)有顯著增加(p<.05)。漸進與30分鐘耐力運動的表現與各生理值,兩藥劑間無著差異。但於30分鐘耐力運動完後,placebo的25-75%用力呼氣流量均大於運動前(5.34±1.07比4.78±1.17 L.s-1)。綜合上述結果,salbutamol對安靜狀態下心跳率影響比運動中顯著;對運動表現無顯著差異。但salbutamol 比placebo有較大的呼吸儲備,推論與呼吸阻力減少有關。

AB - 貝他二型支氣管擴張劑salbutamol是一種選擇性的腎上線素感受體作用劑,能促進支氣管平滑肌的擴張。本實驗以9位男性、無氣喘病的長跑選手(vo2max:60.9±2.34ml.kg-1.min-1)為受試對象,實驗設計採雙盲、平衡(counterbalanced) 重覆測試。每位受試者於實驗前30分鐘吸入霧態2.5mg salbutamol/2.5ml或同等容量的placebo(生理食鹽水)、然後做靜止狀態下肺功能測量,項目包含:肺活量、用力肺活量、1秒用力呼氣量、25-75%用力呼氣流量和最大意願通氣量,再以跑步機做漸進負荷測試(測量值包含:最大攝氣量、最大通氣量、最大心跳率),至少間隔48小時後以同一種藥物做30分鐘耐力運動(測驗值包含:運動中的心跳率、通氣量、攝氣量、二氧化碳排出量、呼吸交換率及最大輸出功與平均功率)。在每次運動測試完後立刻做肺功能測量,比較運動前後的差異。結果顯示吸入salbutamol後的25-75%用力呼氣流量(5.36± 1.06比 4.78 ±1.17 L.s-1)和最大自願通氣量(192.9±28.3比180.0±27.9 L.min-1)及安靜心跳率(63.1±8.4比59.2±7.6 bpm)有顯著增加(p<.05)。漸進與30分鐘耐力運動的表現與各生理值,兩藥劑間無著差異。但於30分鐘耐力運動完後,placebo的25-75%用力呼氣流量均大於運動前(5.34±1.07比4.78±1.17 L.s-1)。綜合上述結果,salbutamol對安靜狀態下心跳率影響比運動中顯著;對運動表現無顯著差異。但salbutamol 比placebo有較大的呼吸儲備,推論與呼吸阻力減少有關。

KW - 支氣管擴張劑

KW - 肺功能

KW - 漸進運動

KW - 耐力運動

KW - 最大攝氧量

KW - salbutamol

KW - bronchodilatoor

KW - pulmonary function

KW - progressive exercise

KW - endurance exercise

KW - maximum oxygen uptake

M3 - 其他報告

BT - 吸入性支氣管擴張劑"Salbutamol"對漸進與耐力運動表現及心肺功能影響

ER -